The species Faecalibacterium prausnitzii typically makes up 5 to 20% of the bacteria in a healthy adult intestine, making it one of the most common gut bacteria. Studies have shown that low levels of F. prausnitzii within the intestines may potentially be linked to Crohn's Disease, colon cancer, obesity, and asthma, although more studies are needed to definitively prove this.
Recently, Faecalibacterium prausnitzii, an acetate-consuming and butyrate-synthesizing gut bacteria, has attracted attention because of its potentially important role in promoting gut health.
Studies have demonstrated that Faecalibacterium may play a probiotic role. F. prausnitzii, the only species known within the Faecalibacterium genus, may exhibit anti-inflammatory effects on colitis by blocking NF-κB expression and IL-8 secretion. Furthermore, F. prausnitzii encourages resistance against potential pathogens.
Chen W, Liu F, Ling Z, Tong X, Xiang C. Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer. PLoS ONE. 2012. 7(6);e39743. doi: 10.1371/journal.pone.00397435
Khan, M T, Duncan, SH et al. The gut anaerobe Facalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. The ISME Journal. 2012. 6;1578–85; doi:10.1038/ismej.2012.5
Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009. 94: 1–8.DOI: http://dx.doi.org/10.1111/j.1574-6968.2009.01514.x
Sokol, H, Pigneur, B et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. The National Academy of Sciences of the USA. 2008.105(43); 16731–36. doi: 10.1073/pnas.0804812105